Adults with obesity who have a prescription for Wegovy but do not have insurance coverage for the drug can now purchase the medication through a new Novo Nordisk direct-to-consumer program.In a March 5 press release, Novo Nordisk announced the launch of NovoCare Pharmacy, a direct-to-patient program that will provide any available dose of Wegovy (semaglutide, Novo Nordisk) for $499 per month. According to a statement from the company sent to Healio, the program provides patients without health insurance or patients whose commercial health insurance does not cover obesity medications a way toRead More